Cargando…

Characterizing the patient experience during neoadjuvant therapy for pancreatic ductal adenocarcinoma: A qualitative study

BACKGROUND: Neoadjuvant therapy (NT) has increasingly been utilized for patients with localized pancreatic ductal adenocarcinoma (PDAC). It is the recommended approach for borderline resectable (BR) and locally advanced (LA) cancers and an increasingly utilized option for potentially resectable (PR)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stevens, Lena, Brown, Zachary J, Zeh, Ryan, Monsour, Christina, Wells-Di Gregorio, Sharla, Santry, Heena, Ejaz, Aslam M, Pawlik, Timothy Michael, Cloyd, Jordan M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2022
Materias:	Observational Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9244990/ https://www.ncbi.nlm.nih.gov/pubmed/35949220 http://dx.doi.org/10.4251/wjgo.v14.i6.1175

Ejemplares similares

Neoadjuvant therapy for pancreatic ductal adenocarcinoma: Opportunities for personalized cancer care
por: Hamad, Ahmad, et al.
Publicado: (2021)

Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Cancer: A Meta-Analysis of Randomized Controlled Trials
por: Cloyd, Jordan M., et al.
Publicado: (2020)

Impact of visitor restriction rules on the postoperative experience of COVID-19 negative patients undergoing surgery
por: Zeh, Ryan D., et al.
Publicado: (2020)

Neoadjuvant treatment strategies for intrahepatic cholangiocarcinoma
por: Akateh, Clifford, et al.
Publicado: (2020)

Neoadjuvant therapy for resectable pancreatic ductal adenocarcinoma: The need for patient-centered research
por: Cloyd, Jordan M, et al.
Publicado: (2020)

National Trends in the Use of Neoadjuvant Therapy Before Cancer Surgery in the US From 2004 to 2016
por: Aquina, Christopher T., et al.
Publicado: (2021)

Factors influencing spiritual wellbeing among pancreatic ductal adenocarcinoma patients receiving chemotherapy
por: Wei, Ling-Ling, et al.
Publicado: (2023)

Adjuvant, neoadjuvant, and experimental regimens in overcoming pancreatic ductal adenocarcinoma
por: Wysocka, Olga, et al.
Publicado: (2016)

An Evaluation of Neoadjuvant Chemoradiotherapy for Patients with Resectable Pancreatic Ductal Adenocarcinoma
por: Jiang, Hui, et al.
Publicado: (2013)

Biochemical Predictors of Response to Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma
por: Awad, Seifeldin, et al.
Publicado: (2020)

Is Neoadjuvant Treatment Justified in Clinical T1 Pancreatic Ductal Adenocarcinoma?
por: Kim, Hyung Sun, et al.
Publicado: (2021)

Neoadjuvant chemoradiation alters the immune microenvironment in pancreatic ductal adenocarcinoma
por: Gartrell, Robyn D., et al.
Publicado: (2022)

Neoadjuvant and Adjuvant Treatments for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: The Current Status of Pancreatic Ductal Adenocarcinoma Treatment in Japan
por: Ei, Shigenori, et al.
Publicado: (2023)

Advancements in Microwave Ablation Techniques for Managing Pancreatic Lesions
por: Ardeshna, Devarshi R., et al.
Publicado: (2023)

Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma: Where Do We Go?
por: Wang, Chenqi, et al.
Publicado: (2022)

Gene expression profiling of pancreatic ductal adenocarcinomas in response to neoadjuvant chemotherapy
por: Sahni, Sumit, et al.
Publicado: (2023)

Neoadjuvant chemotherapy for colorectal liver metastases: A contemporary review of the literature
por: Guo, Marissa, et al.
Publicado: (2021)

Meta‐analysis of the impact of neoadjuvant therapy on patterns of recurrence in pancreatic ductal adenocarcinoma
por: Schorn, S., et al.
Publicado: (2018)

Increased SPARC expression is associated with neoadjuvant therapy in resectable pancreatic ductal adenocarcinoma
por: Hartley, Christopher, et al.
Publicado: (2020)

Role of imaging in evaluating the response after neoadjuvant treatment for pancreatic ductal adenocarcinoma
por: Zhang, Yun, et al.
Publicado: (2021)

Neoadjuvant Treatments for Pancreatic Ductal Adenocarcinoma: Where We Are and Where We Are Going
por: Coppola, Alessandro, et al.
Publicado: (2023)

A neoadjuvant therapy compatible prognostic staging for resected pancreatic ductal adenocarcinoma
por: Zhu, Lingyu, et al.
Publicado: (2023)

Proposal for a New Pathologic Prognostic Index After Neoadjuvant Chemotherapy in Pancreatic Ductal Adenocarcinoma (PINC)
por: Redegalli, M., et al.
Publicado: (2022)

Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma
por: Ruff, Samantha M., et al.
Publicado: (2023)

Prognostic relevance of tertiary lymphoid organs following neoadjuvant chemoradiotherapy in pancreatic ductal adenocarcinoma
por: Kuwabara, Shota, et al.
Publicado: (2019)

Neoadjuvant treatment: A window of opportunity for nutritional prehabilitation in patients with pancreatic ductal adenocarcinoma
por: Trestini, Ilaria, et al.
Publicado: (2021)

Neoadjuvant Immunotherapy for Localized Pancreatic Cancer: Challenges and Early Results
por: Chick, Robert Connor, et al.
Publicado: (2023)

Development of a MicroRNA Signature Predictive of Recurrence and Survival in Pancreatic Ductal Adenocarcinoma
por: Sebastian, Nikhil T., et al.
Publicado: (2021)

Molecular targets for diagnostic and intraoperative imaging of pancreatic ductal adenocarcinoma after neoadjuvant FOLFIRINOX treatment
por: Vuijk, F. A., et al.
Publicado: (2020)

Effect and limitation of neoadjuvant chemotherapy for pancreatic ductal adenocarcinoma: consideration from a new perspective
por: Kurata, Yoshihiro, et al.
Publicado: (2021)

Updates on adjuvant and neoadjuvant treatment strategies for surgically resectable and borderline resectable pancreatic ductal adenocarcinoma
por: Iyengar, Siddharth, et al.
Publicado: (2021)

Organoids Derived from Neoadjuvant FOLFIRINOX Patients Recapitulate Therapy Resistance in Pancreatic Ductal Adenocarcinoma
por: Farshadi, Elham Aida, et al.
Publicado: (2021)

Obstructive sleep apnea predicts pathologic response to neoadjuvant therapy in resected pancreatic ductal adenocarcinoma
por: Shoucair, Sami, et al.
Publicado: (2022)

The outcome of a multidisciplinary approach incorporating neoadjuvant chemoradiotherapy with S1 for resectable pancreatic ductal adenocarcinoma
por: Matsumura, Masaru, et al.
Publicado: (2022)

Defining the Optimal Duration of Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma: Time for a Personalized Approach?
por: Puleo, Amanda, et al.
Publicado: (2022)

Mimics of pancreatic ductal adenocarcinoma
por: Al-Hawary, Mahmoud M., et al.
Publicado: (2013)

Pancreatic ductal adenocarcinoma staging
por: Al-Hawary, Mahmoud M., et al.
Publicado: (2013)

Syndecans and Pancreatic Ductal Adenocarcinoma
por: Betriu, Nausika, et al.
Publicado: (2021)

Models of pancreatic ductal adenocarcinoma
por: Dennaoui, Rayane, et al.
Publicado: (2021)

Burnout Assessment Among Surgeons and Surgical Trainees During the COVID-19 Pandemic: A Systematic Review
por: Shaikh, Chanza Fahim, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ibpd1okpvikn3p19f81675i6k9